title: Decatecholaminisation during sepsis.
authors.affiliation: Institute of Anaesthesiology, University Hospital Zurich, Raemistrasse 100, CH 8091, Zurich, Switzerland. alain.rudiger@usz.ch.
authors.forename: Alain
authors.identifier: 0000-0001-7943-7624
authors.initials: A
authors.lastname: Rudiger
authors.affiliation: Bloomsbury Institute of Intensive Care Medicine, University College London, London, WC1E 6BT, UK.
authors.forename: Mervyn
authors.initials: M
authors.lastname: Singer
mesh_terms: D058647:Adrenergic alpha-2 Receptor Agonists / Q000493:pharmacokinetics / Q000627:therapeutic use; D000316:Adrenergic alpha-Agonists / Q000493:pharmacokinetics / Q000627:therapeutic use; D058671:Adrenergic beta-1 Receptor Antagonists / Q000493:pharmacokinetics / Q000627:therapeutic use; D002395:Catecholamines / Q000009:adverse effects* / Q000502:physiology*; D020927:Dexmedetomidine / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D009638:Norepinephrine / Q000493:pharmacokinetics / Q000627:therapeutic use; D011412:Propanolamines / Q000493:pharmacokinetics / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy* / Q000503:physiopathology*
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists; D058671:Adrenergic beta-1 Receptor Antagonists; D002395:Catecholamines; D011412:Propanolamines; D020927:Dexmedetomidine; C036604:esmolol; D009638:Norepinephrine